Platelet-activating factor (PAF) increase intracellular lipid accumulation by increasing both LDL and scavenger receptors in human mesangial cells

Fragopoulou, Elizabeth; Iatrou, Christos; Antonopoulou, Smaragdi; Ruan, Xiongzhong; Fernando, R.; Powis, Stephen H.; Moorhead, John F.; Varghese, Zac

doi:10.1016/j.lab.2006.01.004

Cited by 12 publications

(14 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The PAF-R is a G protein coupled receptor that is expressed on MCs. The binding of PAF triggers downstream signaling pathways resulting in the production of effector molecules, including arachidonic acid, prostacyclin and TGF-β1 which, in turn, regulate ECM secretion ( 5 , 21 ). The expression of PAF-R mRNA has been detected in all cells of the kidney, and its levels depend on the amount of PAF present.…”

Section: Discussionmentioning

confidence: 99%

“…These alterations are involved in the occurrence and development of DN ( 4 ). Platelet-activating factor (PAF) has been reported to be a strong inflammatory factor and may damage renal tissue in a variety of ways ( 5 ). A high glucose (HG) and lysophosphatidylcholine (LPC) environment increases the expression of inflammatory cytokines, leading to the stimulation of MCs and endothelial cells to continuously synthesize PAF, ECM and protein kinase C-β1 (PKC-β1) ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

“…Platelet-activating factor (PAF) has been reported to be a strong inflammatory factor and may damage renal tissue in a variety of ways ( 5 ). A high glucose (HG) and lysophosphatidylcholine (LPC) environment increases the expression of inflammatory cytokines, leading to the stimulation of MCs and endothelial cells to continuously synthesize PAF, ECM and protein kinase C-β1 (PKC-β1) ( 5 ). PKC is aberrantly activated in the diabetic kidney, which causes an increase in PKC-β1 activity and the deposition of ECM proteins, including Fn and Col IV ( 6 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Atorvastatin prevents glomerular extracellular matrix formation by interfering with the PKC signaling pathway

Xiao

Han

et al. 2018

Mol Med Report

View full text Add to dashboard Cite

Platelet-activating factor (PAF) promotes glomerular extracellular matrix (ECM) deposition, primarily through activation of the protein kinase C (PKC) pathway. The present study was designed to investigate whether atorvastatin, which mediates a protective effect against glomerular ECM deposition and diabetic neuropathy, may interfere with the PKC-transforming growth factor-β1 (TGF-β1) pathway in a model of human mesangial cells (HMCs) exposed to a high glucose (HG) and lysophosphatidylcholine (LPC) environment. HMCs were divided into three treatment groups: Control, high glucose and lysophosphatidylcholine (HG+LPC), and HG+LPC+atorvastatin. Cells were cultured for 24 h. The levels of the ECM-associated molecules collagen IV (Col IV) and fibronectin (Fn) in the supernatant were detected using an ELISA kit. PKC-β1, TGF-β1 and PAF-receptor gene expression was detected by reverse transcription-quantitative polymerase chain reaction. PKC-β1 and TGF-β1 protein expression was detected by western blotting, and the subcellular localization of PKC-β1 was assessed using immunofluorescence. The results indicated that atorvastatin may reduce the secretion of ECM components (Fn and Col IV) in HMCs in a HG and LPC environment, by inhibiting the increase in PAF secretion and the activation of the PKC-TGF-β1 signaling pathway.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Atorvastatin prevents glomerular extracellular matrix formation by interfering with the PKC signaling pathway

Xiao

Han

et al. 2018

Mol Med Report

View full text Add to dashboard Cite

show abstract

“…These bioactive phospholipids mediate such diverse processes as wound healing, physiological inflammation, angiogenesis, apoptosis, reproduction, long-term potentiation and immunoregulatory role [5] . The data suggest that PAF enhances PAF-R expression [6,7] . PAF activates multiple intracellular signaling pathways by binding to PAF-R.…”

Section: Introductionmentioning

confidence: 99%

Therapy for acute pancreatitis with platelet-activating factor receptor antagonists

Chen

Xia²,

Chen³

et al. 2008

WJG

View full text Add to dashboard Cite

Acute pancreatitis (AP) causes release of plateletactivating factor (PAF), which induces systemic effects that contribute to circulatory disturbances and multiple organ failure. PAF is a cell surface secretion of bioactive lipid, which could produce physiological and pathological effects by binding to its cell surface receptor called platelet-activating factor receptor (PAF-R). Studies showed that PAF participates in the occurrence and development of AP and administration of platelet-activating factor receptor antagonists (PAF-RAs) could significantly reduce local and systemic events after AP. PAF has also been implicated as a key mediator in the progression of severe AP, which can lead to complications and unacceptably high mortality rates. Several classes of PAF-RA show PAFRAs significant local and systemic effects on reducing inflammatory changes. As a preventive treatment, PAF-RA could block a series of PAF-mediated inflammatory injury and thus improve the prognosis of AP. This review introduces the important role of PAF-RA in the treatment of AP.

show abstract

“…Os macrófagos expressam diversos receptores que podem interagir com as diferentes formas de LDL modificada. A prova da importância desses receptores é a variedade de fatores inflamatórios estudados que têm sido descritos como moduladores na formação das células espumosas (Fragopoulou et al, 2006;Yun et al, 2009). Esses estudos são importantes para o entendimento da formação destas células, na intenção de propor mecanismos futuros que previnam a captação de oxLDL.…”

Section: Função Dos Macrófagos No Desenvolvimento Da Ateroscleroseunclassified

Sinalização intracelular e expressão de receptores mediados por LDL modificada e peptídeos da apolipoproteínaB-100 em monócitos/macrófagos humanos.

Rios¹

View full text Add to dashboard Cite

show abstract

Platelet-activating factor (PAF) increase intracellular lipid accumulation by increasing both LDL and scavenger receptors in human mesangial cells

Cited by 12 publications

References 41 publications

Atorvastatin prevents glomerular extracellular matrix formation by interfering with the PKC signaling pathway

Atorvastatin prevents glomerular extracellular matrix formation by interfering with the PKC signaling pathway

Therapy for acute pancreatitis with platelet-activating factor receptor antagonists

Sinalização intracelular e expressão de receptores mediados por LDL modificada e peptídeos da apolipoproteínaB-100 em monócitos/macrófagos humanos.

Contact Info

Product

Resources

About